- Home
- RSF vs IMRX Comparison
RSF vs IMRX Comparison
Compare RSF & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- IMRX
- Stock Information
- Founded
- RSF 2016
- IMRX 2008
- Country
- RSF United States
- IMRX United States
- Employees
- RSF N/A
- IMRX N/A
- Industry
- RSF Investment Managers
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- RSF Finance
- IMRX Health Care
- Exchange
- RSF Nasdaq
- IMRX Nasdaq
- Market Cap
- RSF 58.3M
- IMRX 62.7M
- IPO Year
- RSF N/A
- IMRX 2021
- Fundamental
- Price
- RSF $15.21
- IMRX $1.52
- Analyst Decision
- RSF
- IMRX Strong Buy
- Analyst Count
- RSF 0
- IMRX 3
- Target Price
- RSF N/A
- IMRX $11.00
- AVG Volume (30 Days)
- RSF 11.8K
- IMRX 165.5K
- Earning Date
- RSF 01-01-0001
- IMRX 03-20-2025
- Dividend Yield
- RSF 10.61%
- IMRX N/A
- EPS Growth
- RSF N/A
- IMRX N/A
- EPS
- RSF N/A
- IMRX N/A
- Revenue
- RSF N/A
- IMRX N/A
- Revenue This Year
- RSF N/A
- IMRX N/A
- Revenue Next Year
- RSF N/A
- IMRX N/A
- P/E Ratio
- RSF N/A
- IMRX N/A
- Revenue Growth
- RSF N/A
- IMRX N/A
- 52 Week Low
- RSF $14.81
- IMRX $1.00
- 52 Week High
- RSF $16.23
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- RSF 55.83
- IMRX 38.83
- Support Level
- RSF $14.98
- IMRX $1.60
- Resistance Level
- RSF $15.19
- IMRX $1.91
- Average True Range (ATR)
- RSF 0.10
- IMRX 0.11
- MACD
- RSF 0.01
- IMRX 0.01
- Stochastic Oscillator
- RSF 96.00
- IMRX 9.30
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.